BIOPHARMACEUTICAL COLD CHAIN ENGINEERING

Global Cold Chain Validation for Fast Track Regulatory Approval

Modality Solutions provides cold chain engineering, packaging qualification, drug product transport simulation and device functional testing for the biopharmaceutical industry. We design, calibrate, and validate your cold chain network to global regulatory standards. Our novel multi-variable transport simulation laboratory concurrently replicates the five key environmental hazards that impact product quality during transportation: temperature, shock, vibration, humidity, and pressure. Learn more at www.modality-solutions.com.

REGULATORY FILING SUPPORT 

Transport Simulation Laboratory

Thermal Package Engineering

Transport Validation 

COLD CHAIN OPERATIONS

Cold Chain Logistics

Clinical Trial Operations

 Technology

INTEGRATED EXPERTISE

Project Based

Staff Augmentation

Outsourced

Schedule your free one-hour, no obligation consultation.

If you work with us, this is what you can expect:

  • Confidence in your cold chain. Guaranteed.
  • Every engagement led by a principal.
  • Reach out anytime, anywhere, for anything.
  • We solve real problems. Your cold chain will be approved.
  • You will become a cold chain expert.

Let’s start a conversation! 

Call us today at (888) 219-6317

Email: info@modality-solutions.com 

Click here to schedule your free one-hour, no obligation consult.

Go to article: Home | An (in)active pill problemGo to article: EditorialGo to article: SHL Group Company InsightGo to article: Scandinavian HealthGo to article: ContentsGo to article: NSFGo to article: NewsGo to article: AlmacGo to article: Covid-19 executive briefing by GlobalDataGo to article: Gerteis Company InsightGo to article: GerteisGo to article: Digital biomarkers are emerging as important predictive tools to support the gloGo to article: Accurate Biometrics Company Insight Go to article: Accurate BiometricsGo to article: Almost 70 potential Covid-19 drug and experimental compound candidates identifiedGo to article: Datwyler Company Insight Go to article: DatwylerGo to article: Risk assessment of Covid-19 on patients suffering from IBDGo to article: Zenatek Go to article: The pharma industry briefingGo to article: FargoGo to article: Another bump in the road for mumps treatmentGo to article: Last TechnologyGo to article: From Covid-19 to SARS: what becomes of the whistleblowers?Go to article: ButterworthGo to article: Peptomyc: the quest for a ‘universal’ cancer treatmentGo to article: Q&A: is pharma ready to address the health effects of climate change?Go to article: Modality SolutionsGo to article: Not-so-inactive ingredients: a sore spot for patients?Go to article: Beyond M&As: will 2020 be the year of the spin-off? Go to article: VEGA Company Insight Go to article: VEGA AustraliaGo to article: Q&A with Genocea: improving cancer treatment with precise, personalised targetsGo to article: MimotopesGo to article: Pharma Playbook: an inside look at Signals Analytics vast therapeutic database Go to article: ILC Dover Go to article: Deals in brief powered by GlobalDataGo to article: The key list powered by GlobalDataGo to article: Global markets and indices powered by GlobalDataGo to article: Macro-economic indicators (1 of 2) powered by GlobalDataGo to article: Macro-economic indicators (2 of 2) powered by GlobalDataGo to article: EventsGo to article: Next issue